Lantern Pharma (NASDAQ: LTRN), an AI-driven clinical-stage oncology company, announced the completion of a Type C meeting with the U.S. Food and Drug Administration, which provided guidance on the regulatory pathway and design of a planned pediatric trial targeting CNS cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT). The FDA supported Lantern’s proposal for a parallel ATRT cohort and the potential inclusion of spironolactone as a combination agent with LP-184/STAR-001, the company’s lead investigational therapy. Lantern, through its subsidiary Starlight Therapeutics, will submit an IND amendment reflecting the feedback, with trial initiation targeted for Q1 2026. The program holds Rare Pediatric Disease and Orphan Drug designations, and the planned multi-site study will focus on progression-free survival, overall response rate, and quality-of-life outcomes.
To view the full press release, visit https://ibn.fm/iahjk
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
